If you're looking for a biotech player that looks poised to breakout, then put Amarin (AMRN) on your trading radar. This company is a clinical-stage biopharmaceutical player focused on developing improved treatments for cardiovascular disease. Amarin's development programs capitalize in the field of lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease. This stock is off to a fantastic start so far in 2011, with shares up over 76%.
If you take a look at the chart for Amarin, you'll see that this stock has been trading inside of a channel chart pattern for the past two months. During that time, the stock has been trading between the upper-end at around $15 a share and the lower-end at around $13.30 a share. Traders should now watch for a breakout above the upper-end if they're bullish on AMRN.
A move above $15.02 a share and then above its 50-day moving average of $15.74 a share could trigger a big bullish run for AMRN. I would suggest watching for a breakout that comes on big volume above these levels. Look for volume that's close to or well above its three-month average action of 2.9 million shares. This stock has a ton of upside if the breakout does hit because this name was just trading at $19.87 back in early June.One could simply be a buyer of this stock right now and anticipate the breakout above $15.02 a share. I would add to any long position aggressively if you see AMRN trade above $15.74 on big volume. The only way I would get short this stock is if you see it trade below $13.30 on heavy volume, since that level has already triggered a double bottom support zone.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV